相关实验视频

Updated: Jul 27, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

对于治疗不耐药的转移性结直肠癌患者,安洛尼布加PD-1阻塞的可行性和耐受性:一项回顾性探索性研究

Hua Bai¹, Wen-Hui Wang¹, Fan-Fan Zhou¹

¹Department of Oncology, People's Hospital of Zhengzhou, Zhengzhou, People's Republic of China.

Cancer management and research

|February 6, 2024

概括

与PD-1阻断结合的anlotinib在耐火转移性结直肠癌 (CRC) 中显示了初步的疗效. 这种组合疗法为治疗选择有限的患者提供了潜在的新选择,需要进一步调查.

科学领域:

在瘤学瘤学.
医学研究医学研究

背景情况:

转移性结肠直肠癌 (CRC) 对那些对标准治疗不耐药的患者提供了有限的治疗选择.
确定新的治疗策略对于改善高级CRC的结果至关重要.

研究的目的:

评估anlotinib加PD-1阻塞在治疗不耐药的转移性CRC患者中的可行性和耐受性.
在现实临床环境中评估这种组合治疗方案的治疗结果和安全性.

主要方法:

对68名先前接受过治疗的转移性CRC患者的回顾性分析,这些患者接受了anlotinib加PD-1阻塞.
收集和分析人口统计,临床特征,治疗结果和不良事件.
定期跟踪监测药物反应,预后和安全性.

主要成果:

目标应答率 (ORR) 为16.2%,疾病控制率 (DCR) 为76.5%.
无进展生存时间 (PFS) 中位数为5.3个月,总生存时间 (OS) 中位数为12.5个月.
高发生率≥3级不良反应 (89.7%),常见的毒性包括高血压,骨髓抑制,疲劳和手脚综合征.

结论:

安洛丁尼布加PD-1阻塞在不耐治疗的转移性CRC患者中显示了初步令人鼓舞的疗效和可接受的安全性.
建议通过未来的临床试验进一步证实这些发现的有效性.

关键词:

在PD-1的封锁中.安洛丁尼布的使用方法结肠直肠癌是什么意思有效性有效性有效性.关于安全的安全问题

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

相关概念视频

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...